Athersys, Inc (ATHX)

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Athersys Inc (ATHX), where a total of 5,846 contracts have traded so far, representing approximately 584,600 underlying shares. That amounts to about 65.2% of ATHX's average daily trading volume over the past month of 896,775 shares..

Athersys to Host Q3 Financial Results Call on November 15, 2021 at 4:30 pm ET.

Investors in Athersys Inc (ATHX) saw new options begin trading this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATHX options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Athersys, a late-stage clinical company developing MultiStem cell therapy, will be participating in two events at the Cell & Gene Meeting on the Mesa.

Many investors define successful investing as beating the market average over the long term. But the risk of stock...

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Investors in Athersys Inc (ATHX) saw new options begin trading this week, for the January 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 856 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Equity Lifestyle Properties Inc (ELS), where a total of 1,945 contracts have traded so far, representing approximately 194,500 underlying shares. That amounts to about 42% of ELS's average daily trading volume over the past month of 463,555 shares..

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cleveland-Cliffs Inc (CLF), where a total volume of 242,343 contracts has been traded thus far today, a contract volume which is representative of approximately 24.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 93.6% of CLF's average daily trading volume over the past month, of 25.9 million shares..

Athersys partner HEALIOS K.K. announces full enrollment of the TREASURE clinical study evaluating MultiStem® cell therapy for stroke patients.

ATHX earnings call for the period ending June 30, 2021.

Shares of Athersys (NASDAQ:ATHX) increasedin after-market trading after the company reported Q2 results. Quarterly ...

Athersys reports Q2 earnings and positive topline ARDS data evaluating MultiStem® from its partner HEALIOS, K.K. The companies advance partnership.

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader ...

Gainers Nuwellis (NASDAQ:NUWE) shares increased by 5.63% to $4.5 during Friday's after-market session. The market value of their ...

Gainers Applied Molecular (NASDAQ:AMTI) shares increased by 19.38% to $35.54 during Friday's pre-market session. The ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Athersys partner Healios releases positive results from a trial of its MultiStem cell therapy (invimestrocel) for acute respiratory distress syndrome.

Healios announces positive topline clinical data from the ONE-BRIDGE study evaluating MultiStem for acute respiratory distress syndrome (ARDS).

Healios and Athersys deepen their partnership and improve the collaboration agreement to enhance preparations for commercial activity in Japan.

Photo by Anna Shvets from Pexels Now more than ever, regenerative medicine companies like Mesoblast (NASDAQ: MESO), Celularity (NASDAQ: CELU), Athersys (NASDAQ: ATHX), and Pluristem Therapeutics (NASDAQ: PSTI) are among others that understand the importance of creating new, effective pharmaceutical critical care products for unmet needs—especially in a post-pandemic world. Among the most vulnerable patients in the COVID-19 pandemic were undoubtedly elderly sufferers, whose multiple risk factors

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Athersys to Host Second Quarter Financial Results Call on August 9th, 2021.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...